Merz gains Radiesse wrinkle filler
This article was originally published in The Rose Sheet
Executive Summary
German drug company's $253 mil. acquisition of California-based BioForm Medical, announced Jan. 4, provides it with latter's FDA-approved Radiesse wrinkle filler, rounding out its aesthetic product offering and accentuating its presence in the U.S. Merz's pre-acquisition aesthetic portfolio included dermal fillers Belotero (hyaluronic acid) and Novabel (alginate), both available in Europe and undergoing trials to support U.S. approval. Sales of Mederma anti-scarring creams have helped support the firm's U.S. business (1"The Rose Sheet" July 20, 2009). Made of smooth calcium hydroxylapatite microspheres suspended in a gel and designed to stimulate production of new collagen as a patient's own soft tissue replaces the gel carrier, Radiesse competes against Allergan's Juvederm, Medicis' Restylane and Johnson & Johnson's Evolence, among others. BioForm booked sales of about $66.5 mil. in fiscal 2009. Following completion of the acquisition, which Merz expects in March, the firm will relocate its U.S. aesthetics business to BioForm's San Mateo, Calif., headquarters and the combined operation will be renamed Merz Aesthetics
You may also be interested in...
Mederma Anti-Scarring Targets Stretch Marks With New Cream
Merz Pharmaceuticals is launching its newest Mederma cream with a specific type of scarring in its crosshairs - striae, or stretch marks
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.